Arthrosi Therapeutics, headquartered in San Diego, is focused on bringing its lead candidate pozdeutinurad (AR882) to market for the treatment of gout and tophaceous gout. Pozdeutinurad is designed as a next-generation, highly potent and selective URAT1 inhibitor that has already demonstrated superior serum urate reduction and complete tophi resolution in Phase 2b studies. The company has fully enrolled two pivotal, 12-month randomized, double-blind, placebo-controlled Phase 3 trials—REDUCE 1 and REDUCE 2—and expects top-line data in Q2 2026. Proceeds from its most recent financing will fund completion of these trials and related development activities. Arthrosi’s strategy is to position pozdeutinurad as a best-in-class therapy addressing the unmet needs of roughly 13 million U.S. gout patients, including about 2 million with tophaceous gout. The company touts a management team with strong execution experience and has attracted a syndicate of life-science investors who see significant commercial potential. While revenue has not yet been generated, the firm’s late-stage clinical progress and sizable Series E raise highlight growing investor confidence in its asset.

Total raised

$243M

Funding rounds

3

Latest round

Series E

Latest activity

Oct 2025